![](https://news.europawire.eu/wp-content/uploads/2023/03/sanofi-144x144.jpg)
(IN BRIEF) Sanofi’s phase 3 study for its drug tolebrutinib has shown promising results in treating non-relapsing secondary progressive multiple sclerosis (nrSPMS), a condition with no current approved therapies. The HERCULES study revealed that tolebrutinib successfully delayed disability progression in … Read the full press release